Psilocybin reorganizes brain activity around context

With their eyes closed, participants at Monash Biomedical Imaging moved through a five-minute movie, five minutes of rest, five minutes of audio-guided meditation and seven minutes of music after taking psilocybin. The 62 healthy adults had never taken psychedelics before, giving researchers a closely tracked first experience rather than an average drawn from experienced users.

The five-year study, published in Nature, combined EEG (electroencephalography, which records electrical brain activity) with functional MRI, which maps changes in brain activity and connectivity. An artificial-intelligence system analyzed those signals moment by moment instead of averaging them across the group, allowing the team to examine how each person’s brain changed in each setting.

The result complicates the familiar picture of psychedelic disruption. Brain networks that help process the inner world and the world around us became less distinct under psilocybin, but their activity reorganized into patterns aligned with the context: resting, listening to music, meditating or watching a movie. The effect was strongest among participants who described a more positive experience.

That matters because psilocybin’s possible therapeutic effect may depend partly on the experience itself, not only on the drug’s chemistry. Psilocybin interacts with a type of serotonin receptor and induces neural plasticity, according to the researchers. The study supports the idea that what people do, attend to and experience during a session can shape the brain’s response, rather than serving as mere background.

So what changes in practice? Not treatment today, but a route toward measuring how an individual responds during a session and eventually predicting who may benefit. The researchers found that stronger brain reorganization was associated with greater positive psychological changes the following day. That link came from healthy volunteers, however; the next test is whether these individual brain signatures generalize to patients and predict lasting therapeutic change. Australia’s authorization of psilocybin for treatment-resistant depression provides regulatory context, but the study itself is evidence about brain responses, not proof of clinical effectiveness.